The use of cell secretomes opens a new era of advanced therapies

This chair announces the successful union of two investigative powers; academic with the Autonomous University of Madrid, and biopharmaceutical industry with Peaches Biotech. Selective secretomes are the basis proposed by Peaches as a new disruptive model for obtaining drugs. One more step towards evolution that will allow the democratization of advanced therapies which adds to the research carried out in this field by the Department of Surgery of the Faculty of Medicine of the UAM. 

Under the title "The secretome as medicine of the 21st century", the Autonomous University of Madrid and Peaches, have started an informative cycle this Thursday that has highlighted the potential of the secretome as an approach for new treatments of pathologies of high prevalence. The meeting was attended by the country's leading experts in both clinical and regulatory areas. The therapeutic advantages of secretomes have been demonstrated and the regulatory field that has to be established for their use and distribution on a large scale has been debated. 

Throughout the day, numerous studies have been presented on the behavior and function of selective secretomes that open the door to a new generation of biological drugs such as immunomodulators, anti-inflammatories and tissue regenerators that currently lack optimal treatment. In this field, Peaches has a patent built for selective secretome, called PRS; based on co-culture methods in which the communication between M2 macrophages and the different tissue cells damaged or attacked by virus bacteria is reproduced. 

The secretome represents the evolution of stem cell therapies. This is the language that stem cells emit for the regeneration of damaged tissue. These cells identify their environment and provide the appropriate orders for the tissue to start the regeneration process. These chemical messages are collected, isolated and would form a new biological medicine. 

In this first meeting of the UAM-PEACHES Chair, some of the advantages of secretomes over cell therapies have been shown. They are more stable than cells and can be kept cold at temperatures that are easier to handle. Important elements so that their application means a reduction in manufacturing costs, since they are much easier to use, to distribute and transport, as well as storage, making them more accessible to doctors and, consequently, to patients. 

"Cellular communication is what we want to find out with this UAM-PEACHES chair or at least give a first hint of the language of the secretome and with that try to reach the hospital and the clinic so that patients benefit from these investigations," he comments. Dr. García Arranz, one of the directors of the chair. Dr. García Olmo, also director of the Chair, affirms: "thanks to the creation of this chair, a synergy arises between the University and the company PEACHES which, through clinical researchers and the UAM, will promote progress and cell therapy research. 

Using the language between the immune system and the cells of different tissues, Peaches' research provides multiple therapeutic applications, such as immunomodulatory and anti-inflammatory drugs. Your PRS platform; It represents a step forward in advanced therapies and a new approach in regenerative medicine treatments, as well as cytokine storms as a reaction to infections. 

In the words of the scientific director of Peaches, Dr. Pedro Lapuente: “we have made the cells talk to each other and we have understood the language of the secretomes that they emit. Now it is time to continue investigating the clinical applications that the knowledge of this cellular language gives us”. The UAM-PEACHES Chair is directed by professors Damián García-Olmo and Mariano García Arranz, both with a proven track record in advanced cell therapy with stem cells. 

The objective of this UAM-PEACHES Chair is the promotion of research and the dissemination of knowledge in the field of cell therapy and regenerative medicine, especially in the development of new advanced therapy treatments, based on mesenchymal stem cells and secretomes. that they emit to carry out their work of repair and regeneration. This use of selective secretomes is the basis of a new model for obtaining drugs.